13-May-2024
No headlines found.
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
Business Wire (Fri, 10-May 8:50 AM ET)
Business Wire (Thu, 9-May 8:50 AM ET)
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
Business Wire (Mon, 1-Apr 4:02 PM ET)
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
Business Wire (Wed, 27-Mar 8:30 AM ET)
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of May 13, 2024, OMER stock price climbed to $3.75 with 131,987 million shares trading.
OMER has a beta of 3.64, meaning it tends to be more sensitive to market movements. OMER has a correlation of 0.15 to the broad based SPY ETF.
OMER has a market cap of $217.29 million. This is considered a Small Cap stock.
In the last 3 years, OMER stock traded as high as $18.86 and as low as $.92.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, IWN, SCHA.
OMER has underperformed the market in the last year with a return of -38.1%, while the SPY ETF gained +27.8%. In the last 3 month period, OMER fell short of the market, returning -1.8%, while SPY returned +4.3%. However, in the most recent 2 weeks OMER has outperformed the stock market by returning +19.0%, while SPY returned +2.5%.
OMER support price is $3.35 and resistance is $3.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER stock will trade within this expected range on the day.